1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
68D8D87229E5B0E578525849D00439A81
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/insights/8D8D87229E5B0E578525849D00439A81?OpenDocument
18
19OpenDocument
203.226.243.226
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB






Products & Services >> Best Practice Database >>Archived Research Alerts >>September 2019 Research

SEPTEMBER 2019 Research Alert

This month we added five new studies to the Best Practice Database, the research repository for Best Practices, LLC. This month's new studies involve two topical areas: co-pay accumulators and patient advocacy groups. Two of the new studies are focused on the timely issue of co-pay accumulator programs: the first looks at the impact that these payer programs are having on patients' out-of-pocket costs; the second study examines the strategies pharma is using to counter the programs and ensure patient access. The remaining three studies examine the current state of patient advocacy group collaboration: the third study examines effective structure and communication approaches for pharma; the fourth looks at creating effective advocacy partnerships, and the final study is focused on the use of technology and current trends in the patient advocacy space.

The new Best Practices, LLC studies listed below under Newly Added Research explore how leading companies have made their operations more effective across these different areas.


Download: Co-pay Accumulator Programs: Impact and Challenges (5574)

Best Practices, LLC conducted this study to highlight the impact of payer-imposed “co-pay accumulator” programs (CAs) on specialty manufacturers and their patients. The study will help market access leaders better understand the threat, impact and challenges that co-pay accumulator programs present to the pharmaceutical industry and patients.


Download: Co-pay Accumulator Programs: Effective Pharma Strategies & Tactics for Ensuring Patient Access (5575)

This study looks at how organizations are measuring the success of their CA mitigation strategies and working with patients to ease out-of-pocket costs. Market access leaders can use this research to create and deploy effective CA mitigation strategies and ensure patient-centric reimbursement solutions.


Download: Patient Advocacy 2020: Optimizing Structure of the Advocacy Function in the United States (5576)

Best Practices, LLC conducted this benchmarking research to examine the ideal structures, skill sets, and staffing for pharma teams that work with advocacy groups in the United States. This study also identifies the preferred communication channels for patient advocacy groups.


Download: Patient Advocacy 2020: Optimizing Advocacy Partnerships to Improve Access and Boost Patient Voice in the United States (5577)

This study delivers benchmarks around performance measurement, collaboration timing and grants. Also, there are qualitative insights on managing advocacy relationships within controversial disease states.


Download: Patient Advocacy 2020: Use of Technology, Current Trends & Future Direction in the United States (5578)

Pharma advocacy groups need to continually be aware of current and emerging technology trends in patient advocacy to be effective partners. Best Practices, LLC undertook this benchmarking research to examine the winning strategies and best practices in patient advocacy in the United States.